Products Cited in Publications Worldwide 4-(Tris(4-methyl-1H-pyrazol-1-yl)methyl)aniline

4-(Tris(4-methyl-1H-pyrazol-1-yl)methyl)aniline

Bradley B. Garrison; Joseph E. Duhamel; Nehemiah Antoine; Steven J. K. Symes; Kyle A. Grice; Colin D. McMillen; Jared A. Pienkos

DOI:

Abstract

4-(tris(4-methyl-1H-pyrazol-1-yl)methyl)aniline was prepared in a 63% yield utilizing a C–F activation strategy from a mixture of 4-(trifluoromethyl)aniline, 4-methylpyrazole, and KOH in dimethylsulfoxide (DMSO). The identity of the product was confirmed by nuclear magnetic resonance spectroscopy, infrared spectroscopy, mass spectrometry, and single-crystal analysis. An analysis of crystals grown from the layering method (CH2Cl2/acetone/pentane) indicated two distinct polymorphs of the title compound. Moreover, density functional theory calculations utilizing the MN15L density functional and the def2-TZVP basis set indicated that 4-(tris(4-methyl-1H-pyrazol-1-yl)methyl)aniline forms with similar energetics to the previously reported unmethylated analog.

Keywords

tris(pyrazolyl)methane ; ligand ; C–F activation ; crystallography ; polymorphs ; DFT

Purchased from AmBeed

Fomepizole

A1959407554-65-698%

Fomepizole

10.0/5g

Detail
Leflunomide impurity A

A871006455-14-198%

Leflunomide impurity A

103.0/500g

Detail